Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00224133 · ClinicalTrials.gov registry record · Phase 3

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

A Phase 3 study of Benign Prostatic Hyperplasia, sponsored by Watson Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
661
Enrollment target
20
Study locations

NCT00224133 is a Phase 3 study of Benign Prostatic Hyperplasia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 661 participants, above the 529-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00224133, a Phase 3 study of Benign Prostatic Hyperplasia, has completed, sponsored by Watson Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
661 participants
Enrollment target
20
Study locations

Study Summary

A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

Conditions Studied

Benign Prostatic Hyperplasia

Interventions

  • DRUG Silodosin

Study Locations (20)

California

  • - Anaheim
  • - Carmichael
  • - Culver City
  • - Fresno
  • - Irvine
  • - La Jolla
  • - Laguna Woods
  • - Long Beach
  • - Newport Beach
  • - San Bernardino
  • - San Diego
  • - Tarzana
  • - Torrance

Alabama

  • - Birmingham
  • - Huntsville

Colorado

  • - Aurora
  • - Wheat Ridge

Arizona

  • - Tucson

Connecticut

  • - Waterbury

Florida

  • - Aventura

Trial Details

FieldValue
Enrollment Target 661 participants
Start Date 2005-09
Est. Completion 2007-04
Phase Phase 3

Sponsor

Watson Pharmaceuticals

28 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00224133

The ClinicalTrials.gov registry entry for NCT00224133 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 661 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 529-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (25% higher). The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Silodosin is the first listed.

NCT00224133 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Colorado.

Frequently Asked Questions

What is clinical trial NCT00224133 about?

NCT00224133 is a clinical study titled "The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months". A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

What is the current status of trial NCT00224133?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 661 participants. The study started on 2005-09. Estimated completion is 2007-04.

What conditions does trial NCT00224133 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.

What interventions are being tested in trial NCT00224133?

The interventions under investigation include: Silodosin (DRUG).

Who is sponsoring clinical trial NCT00224133?

This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00224133 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Benign Prostatic Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Benign Prostatic Hyperplasia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.